SCHEMBL20022490

SCHEMBL20022490

CCOc1cn(-c2c(C)ccnc2C)nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)cc1F

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MET P08581 10/20 0.60
AXL P30530 6/20 0.60
AURKA O14965 1/20 0.60
ABL1 P00519 1/20 0.60
LCK P06239 1/20 0.60
SRC P12931 1/20 0.60
FER P16591 1/20 0.60
CDK8 P49336 1/20 0.60
TYRO3 Q06418 1/20 0.60
MERTK Q12866 1/20 0.60
MAP2K5 Q13163 1/20 0.60
AURKB Q96GD4 1/20 0.60
KDR P35968 7/20 0.55
PDGFRA P16234 3/20 0.55
KIT P10721 1/20 0.55
FGFR2 P21802 1/20 0.55
CSF1R P07333 2/20 0.48
PDGFRB P09619 2/20 0.48
FLT3 P36888 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20022461 0.89 MET (0.63) METAXLAURKAABL1LCK
SCHEMBL20022451 0.87 MET (0.56) METAXLAURKAABL1LCK
SCHEMBL20022487 0.86 MET (0.78) METAXLAURKAABL1LCK
SCHEMBL20022464 0.85 MET (0.59) METAXLAURKAABL1LCK
SCHEMBL20022462 0.85 MET (0.57) METAXLAURKAABL1LCK
SCHEMBL20022489 0.85 MET (0.57) METAXLAURKAABL1LCK
SCHEMBL167761 0.85 MET (0.75) METAXLAURKAABL1LCK
SCHEMBL18163495 0.85 MET (0.58) METAXLAURKAABL1LCK
SCHEMBL167836 0.84 MET (0.75) METAXLAURKAABL1LCK
SCHEMBL20022493 0.84 MET (0.58) METAXLAURKAABL1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10934274-B2 Quinoline derivatives as TAM RTK inhibitors QURIENT CO., LTD. (KR) 2021-03-02 US disclosed
US-20180093968-A1 QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2018-04-05 US disclosed
US-20180093968-A1 QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2018-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934274-B2 Quinoline derivatives as TAM RTK inhibitors TYRO3, MERTK, AXL MET 5/4885AXL 3/4885AURKA 660/4885
US-20180093968-A1 QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS TYRO3, MERTK, AXL MET 5/4885AXL 3/4885AURKA 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.